---
document_datetime: 2025-07-17 14:26:28
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/aripiprazole-zentiva-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: aripiprazole-zentiva-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.2987366
conversion_datetime: 2025-12-19 02:05:00.576787
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Aripiprazole Zentiva

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproductlifecycleprocedures,youmayneed to alsorefer toEPAR-Procedural steps taken and scientific information after authorisation (archive).

| Applicationnumber   | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|---------------------|-----------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Article 61(3) /     | -Notification acc.Article61(3)-Accepted | 15/07/2025                          |                                          | PL                              |           |

1Notifications areissuedfortypeIvariations andArticle61(3)notifications(unlesspartofagroupincludinga typeIIvariationorextensionapplicationoraworksharingapplication).Opinions areissuedforallotherprocedures.

3SmPC(Summary ofProductCharacteristics),Annex II,Labelling,PL(PackageLeaflet).

2 A Commission decision(CD) is issued for procedures that affect the terms of the marketing authorisation(e.g. summary of product characteristics, annex II, labelling,package leaflet).The CDisissuedwithintwomonthsof theopinionforvariationsfallingunderthescopeofArticle23.1a(a)ofRegulation(EU)No.712/2012,orwithinoneyearforotherprocedures.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/N/0000284695                      | Update of the package leaflet with revised contactdetailsoflocalrepresentatives. Furthermore,the PIhas been brought in line with the latest QRD template (version 10.4).                                                                                                                                |            |                        |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------------------|
| Variation type IB / EMA/VR/0000256773 | C.1.7 Deletion of:-C.I.7.a a pharmaceutical form - Accepted C.1.7.a (Type IB)Deletion of the presentations related to the orodispersible tablets pharmaceutical form. The following presentations will be deleted: 10 mg (EU/1/15/1009/021-23),15mg (EU/1/15/1009/024-26), 30 mg (EU/1/15/1009/027-29). | 17/06/2025 | SmPC, Labelling and PL |